Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self‑renewing, and Capable of Persistent Anti-Tumor Effects
June 11, 2018 07:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 11, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that data from the...